An Expert View from Katie Nelson, senior asset manager, and Mairi Dillon, ecosystem manager, at Kadans Science Partner.
The government's ambition to solidify the UK's status as a scientific superpower has been widely discussed, but what does this aspiration truly involve? In essence, it requires far more than just a title – it demands a financial commitment and measures to enhance the UK's appeal to global talent and investment. This strategic move will empower the UK to enhance its infrastructure and expertise, both of which are pivotal for industry growth.
The components of this industry, including physical assets, real estate, and diverse scientific infrastructure, alongside the skilled workforce operating within these facilities and driving industry advancement, will ultimately bridge the gap between the lofty 'superpower' label and genuine achievement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze